Results 161 to 170 of about 790,096 (261)

A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). [PDF]

Pharmaceuticals (Basel)
Wang C, Zhou C, Hou S, Fan W, Qian W, Ren Y, Chen X, Pan C, Guo Q, Guo H, Guo Y.   +10 more
europepmc   +1 more source

Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects. [PDF]

Int J Retina Vitreous
Zong Y, Fan Q, Huang L.
europepmc   +1 more source

Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025). [PDF]

J Manag Care Spec Pharm
Gilbert Farrar K, Masters NB, Do D, Stucky N, Goodwin Cartwright BM.   +4 more
europepmc   +1 more source

Pharmaceuticals Industry Strategy Group directions paper

, 2008
This paper provides an overview of the Australian and global pharmaceuticals industries, a discussion of the barriers and drivers to global and Australian industry, a strategic framework for how the industry will achieve a sustainable future and ...

core  

Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? [PDF]

Int J Clin Pharm
Burton E, Coakley KE, Gaynor S, McDonagh M, Palmer C, Sahm LJ, O'Reilly S, Biologics Impact on Patient Care and Treatment (Bio ImPAcT) Consortium.   +7 more
europepmc   +1 more source

Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure [PDF]

This paper investigates patterns of industrial dynamics and competition in the pharmaceutical industry, with particular reference to the consequences of patent expiry in different countries.
Magazzini, Laura, Pammolli, Fabio, Riccaboni, Massimo   +2 more
core  

From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development. [PDF]

Bioanalysis
Ribes S, Rosenbaum M, Hartmann L, Allmannsberger L, Poetzl J.   +4 more
europepmc   +1 more source

Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: <i>A Clinical Experience</i>. [PDF]

Saudi Med J
Najjar RH, Alrashid SO, Almahfouz RF, Alzahrani HT, Aleissa MY, Hakami AR.   +5 more
europepmc   +1 more source

Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany. [PDF]

BMC Nephrol
Kaufhold I, Lewkowicz D, Seidel D, Brinkkoetter PT, Kron F.   +4 more
europepmc   +1 more source

Expanding Patient Access to Advanced Therapies. [PDF]

BioDrugs
Guillen E, Hidalgo-Simon A.
europepmc   +1 more source